We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Midatech Pharma Plc | MTPH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 18.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 18.00 | 18.00 |
| Top Posts |
|---|
Posted at 10/6/2022 07:33 by manual dexterity Midatech Pharma PLCMTX110 Study to be Presented at ISPNO 2022 New Chairman. Same chairman as Sareum Holdings plc. |
Posted at 01/6/2022 15:04 by manual dexterity Certainly with the cash element I would categorise both MTPH and EVG as similar and very interesting in their pipeline. Both share prices have been demolished and there is some overlay between the two.However BOTH have very interesting pipelines. Midatech Pharma PLC (AIM:MTPH) soared 32% to 13.5p after its MTX110 treatment for recurrent glioblastoma, a form of cancer, was given fast track designation by the Food and Drug Administration. The drug-delivery technology company said the fast track process will facilitate the development and accelerate the review of treatments for serious conditions. "Receiving Fast Track designation for MTX110 is an important milestone for the development of the drug as it demonstrates the need for novel and effective treatment options for this currently universally fatal disease," Dmitry Zamoryakhin, chief scientific officer, said. |
Posted at 01/6/2022 14:55 by manual dexterity Indeed he is. MTPH has fallen from around the 60p levels so assuming last placing was at 28p per share to raise £10million there will be some interest around these levels. |
Posted at 01/6/2022 12:50 by manual dexterity I've added MTPH to my BIOTECH portfolio. |
Posted at 14/1/2022 00:13 by shujja1 Charlie Malik (@CharliemalikMr) Tweeted:#MTPH [...] |
Posted at 05/1/2022 14:49 by david gruen Very similar to the IMM chart. Looks ready to test the top of the chanel (50p in the case of MTPH.) |
Posted at 29/12/2021 21:17 by shujja1 Charlie Malik (@CharliemalikMr) Tweeted:#MTPH 🦅🇪&# |
Posted at 03/12/2021 07:53 by david gruen Midatech Pharma PLC03 December 2021 REACH 3 December 2021 Midatech Pharma PLC ("Midatech" or the "Company") Midatech presenting at MelloMonday Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce it is presenting at MelloMonday on Monday 13 December 2021, via a Zoom Webinar. The Company will be attending MelloMonday on Monday 13 December 2021 taking place from 5.00pm to 9.30pm GMT. Stephen Stamp, Midatech's CEO and CFO, will be presenting and taking questions from participants. |
Posted at 29/11/2021 22:17 by sharesoc In case you missed it, you can watch our webinar with Midatech Pharma PLC (MTPH) – 18 November 2021 here: Full membership will be required to watch the recording. You can sign up for full ShareSoc membership here: hxxps://www.sharesoc |
Posted at 24/11/2021 07:34 by david gruen Midatech Pharma PLC24 November 2021 REACH 24 November 2021 Midatech Pharma PLC ("Midatech" or the "Company") Midatech presenting at the Shares and AJ Bell Webinar Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that the Company's CEO and CFO, Stephen Stamp, will be presenting at the Shares and AJ Bell investor webinar on Wednesday 1 December 2021 at approximately 19.20 GMT. The Shares and AJ Bell evening webinars are an opportunity for senior board directors from quoted companies to make a presentation about their company and update existing and potential investors on their business plans. Shareholders and potential investors can register to join the webinar for free at: hxxps://www.sharesma |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
